Key Takeaways
- Intercept aims to develop multi-virus countermeasures, inspired by rapid responses to COVID-19.
- Supported by prominent advisors, including former FDA official Peter Marks and Operation Warp Speed leader Moncef Slaoui.
- Private philanthropy is stepping in as federal funding for viral research remains stagnant.
Intercept’s Mission in Viral Research
The initiative, known as Intercept, is set to innovate across viral research, inspired by the successful rapid development of COVID-19 vaccines and treatments. Spearheaded by researcher Jesse Veesler, this project will focus on creating strategies to combat multiple viruses simultaneously.
To guide its mission, Intercept has enlisted notable advisors who bring substantial experience in public health and pharmaceutical development. Peter Marks, a former senior FDA official, and Moncef Slaoui, the executive behind the US COVID-19 vaccine rollout, are key figures on the advisory board.
A primary challenge for Intercept pertains to the vast diversity of viruses. Veesler highlights the daunting task that this presents, stating, “The diversity of viruses is just too large and seems daunting, so people don’t even try.” This complexity fuels the group’s interest in innovative technologies, such as air-cleaning systems employing ultraviolet light to eliminate viruses from environments, akin to how municipalities purify drinking water.
Funding dynamics play a crucial role in Intercept’s endeavors. The National Institute of Allergy and Infectious Diseases (NIAID) allocates approximately $6.5 billion annually towards virus research. However, stagnant budgets have prompted an increase in private philanthropy to fill the gaps. Benefactors like Stripe’s Collison brothers have emerged as significant contributors. Following their “fast grants” initiative during the pandemic, they, alongside others, have pledged $650 million to establish the Arc Institute in Palo Alto. This institute is recognized for employing AI models in biological research, furthering the field’s advancement.
These developments signal a shift towards collaborative efforts between public and private sectors in the realm of viral research, as Intercept paves the way for new strategies to address viral threats efficiently. Veesler expresses optimism about this collaborative approach, appreciating the willingness of partners to explore uncharted territories instead of settling for the current status quo.
The content above is a summary. For more details, see the source article.